Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 12,548 matching trials from the live ClinicalTrials.gov search.

Filters: Miami, Florida Clear all

Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions: Dapagliflozin, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 150 Years
Enrollment: 504 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 25
States / cities: Alexander City, Alabama • Fort Payne, Alabama • Beverly Hills, California + 21 more

Conditions: Diabetes Mellitus, Type 1
Interventions: islet cell transplantation; Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Corneal Foreign Body
Interventions: Corneal Foreign Body Removal; Procedure
Lead sponsor: Kendall Healthcare Group, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Colorectal Cancer, CRC
Interventions: Fecal Immunochemical Test, Septin9 Test; Other
Lead sponsor: University of Miami; Other
Eligibility: 40 Years to 65 Years
Enrollment: 646 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hemostasis
Interventions: Fibrin Pad, SURGICEL™; Drug · Device
Lead sponsor: Ethicon, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 11
States / cities: Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 6 more

Conditions: COVID-19
Interventions: Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™, Placebo; Drug
Lead sponsor: Jose David Suarez, MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Obesity
Interventions: LLF580, Placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Jacksonville, Florida • Miami, Florida • Overland Park, Kansas + 4 more

Conditions: HIV Infections
Interventions: Anti-HIV Immune Serum Globulin (Human); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 2 Years to 12 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 37
States / cities: Birmingham, Alabama • Long Beach, California • Los Angeles, California + 26 more

Conditions: Hypertension
Interventions: Aliskiren; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 43
States / cities: Los Angeles, California • Riverside, California • Santa Monica, California + 38 more

Conditions: Asthma
Interventions: placebo, mometasone 400 mcg, mometasone 200 mcg; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Drug-drug Interaction
Interventions: Aspirin, BAY3389934; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Ovarian Cancer
Interventions: Exercise and medical nutrition; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: New Haven, Connecticut • Miami, Florida

Conditions: HIV Infections, Pregnancy
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 60 Years
Enrollment: 1,496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 58
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 32 more

Conditions: Dyslipidemia
Interventions: Placebo, Pravastatin, Dalcetrapib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 33
States / cities: Mobile, Alabama • Scottsdale, Arizona • Newark, Delaware + 30 more

Conditions: Covid19, SARS (Severe Acute Respiratory Syndrome), SARS Pneumonia, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Pneumonia, Pneumonia, Viral
Interventions: Fostamatinib, Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 9
States / cities: Orange, California • Washington D.C., District of Columbia • Hialeah, Florida + 6 more

Conditions: Acute Myocardial Infarction, ST Elevation MI, STEMI
Interventions: Nitric Oxide, Placebo; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 11
States / cities: Mobile, Alabama • Miami, Florida • Chicago, Illinois + 6 more

Conditions: Geographic Atrophy, Macular Degeneration
Interventions: Avacincaptad pegol (ACP); Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: Not listed
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 58
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Laguna Hills, California + 53 more

Conditions: Prevention of Stroke or Systemic Embolism, Atrial Fibrillation
Interventions: Asundexian (BAY2433334), Apixaban, Asundexian matching placebo, Apixaban matching placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 14,830 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 163
States / cities: Dothan, Alabama • Fairhope, Alabama • Mobile, Alabama + 144 more

Conditions: Asthma
Interventions: ELLIPTA DPI, GSK MDI, AZ MDI; Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 20
States / cities: Huntington Beach, California • Aventura, Florida • Clearwater, Florida + 17 more

Conditions: CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, NTRK Family Gene Mutation, PI3K Gene Mutation, ROS1 Gene Mutation, KRAS G12C Mutation
Interventions: Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 435
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 306 more

Conditions: Psoriatic Arthritis
Interventions: Zasocitinib, Active Comparator, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 1,583 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 50
States / cities: Chandler, Arizona • Phoenix, Arizona • Fountain Valley, California + 44 more

Conditions: Hepatic Insufficiency
Interventions: AG-013736; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: Miami, Florida • Orlando, Florida

Conditions: Hematological Malignancies
Interventions: Magrolimab, Azacitidine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 26
States / cities: Duarte, California • La Jolla, California • Los Angeles, California + 20 more

Conditions: COPD
Interventions: myAirvo3, Pulse oximeter; Device
Lead sponsor: Temple University; Other
Eligibility: 30 Years and older
Enrollment: 642 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 25
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 20 more

Search by objective public record fields.

DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction

Islet Cell Transplantation Alone in Patients With Type I Diabetes Mellitus: Steroid-free Immunosuppression

Magnet for Corneal Foreign Bodies

Addressing Colorectal Cancer in South Florida Firefighters

The Fibrin Patch Soft Tissue Study

LACTYFERRIN™ Forte and ZINC Defense™ and Standard of Care (SOC) vs SOC in the Treatment of Non-hospitalized Patients With COVID-19

Safety Study of LLF580 in Obese Volunteers

A Phase I/II Study of Hyperimmune IVIG in Slowing Progression of Disease in HIV-Infected Children

8-week Randomized, Open-label Study to Evaluate Food Effect on Efficacy and Safety of Oral Aliskiren 300 mg in Patients With Hypertension

Acute Effect of Mometasone on Beta-adrenergic Airway and Airway Vascular Relaxation in Severe Asthma

A Study to Learn About How Safe BAY3389934 is and How it Affects Blood Clotting When Given Alone or With Aspirin in Healthy Participants

Trial of Exercise and Lifestyle for Women With Ovarian and Endometrial Cancer

The Safety and Effectiveness of Zidovudine in HIV-Infected Pregnant Women and Their Infants

A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C)

Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects

Nitric Oxide in Myocardial Infarction Size

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

Evaluation Of Hepatic Impairment On AG-013736 Pharmacokinetics

Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies

myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home